Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardonilizumab + Lenvastinib in Resectable Renal Clear Cell Carcinoma
NCT06574412Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Sep 2024
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies
01
Overview
A Phase 2 trial of cadonilimab in clear cell renal cell carcinoma (ccRCC), sponsored by The First Hospital of Jilin University. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06574412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574412.